ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Organogenesis Holdings Inc

Organogenesis Holdings Inc (ORGO)

2,42
-0,06
(-2,42%)
Fermé 06 Juin 10:00PM
2,42
0,00
(0,00%)
Après les heures de négociation: 1:59AM

Organogenesis Holdings Inc (ORGO) Action

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
2,42
( -2,42% )
Prix Achat
2,40
Prix Vente
2,50
Volume échangé
673 632
2,41 Fourchette du Jour 2,5091
2,04 Plage de 52 semaines 7,0771
Cap du marché
Clôture Veille
2,48
Ouverture
2,45
Dernière Transaction
5
@
2.47
Dernière heure de transaction
Volume financier
US$ 1 651 828
VWAP
2,4521
Volume moyen (3 m)
US$ 1 518 238
Actions en circulation
128 674 548
Rendement du Dividende (LTM)
Ratio Cours sur Bénéfices
-22,16
Bénéfice par action (BPA)
-0,12
Chiffre d'affairess (LTM)
514,7M
Bénéfice net (LTM)
2,72M

À propos de Organogenesis Holdings Inc

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion p... Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts. Show more

Secteur
Healthcare
Industrie
Pharmaceuticals
Siège social
Canton, United States
Fondé
-
Organogenesis Holdings Inc est coté dans le secteur Healthcare de la NASDAQ avec le ticker ORGO. Le dernier cours de clôture d'Organogenesis était de US$2,48. Au cours de la dernière année, les actions de Organogenesis ont été négociées dans une fourchette de prix de US$ 2,04 à US$ 7,0771.

Organogenesis compte actuellement 128 674 548 actions en circulation. La capitalisation boursière d'Organogenesis est de US$311,39 million. Organogenesis a un ratio cours/bénéfice (ratio PE) de -22.16.

ORGO Dernières nouvelles

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.19-7.279693486592.612.6782.189521712.40365691CS
40.22102.22.7852.0414008232.50247083CS
12-0.2-7.633587786262.622.7852.0415223332.41911572CS
26-2.52-51.0121457494.945.9052.0412250493.24104975CS
52-0.44-15.38461538462.867.07712.0412186994.04320674CS
156-1.58-39.547.07711.9610989753.80358361CS
260-14.07-85.32443905416.4917.51.79510729585.09150944CS

ORGO - Frequently Asked Questions (FAQ)

What is the current Organogenesis Holdings Inc share price?
The current share price of Organogenesis Holdings Inc is US$ 2,42
How many Organogenesis Holdings Inc shares are in issue?
Organogenesis Holdings Inc has 128 674 548 shares in issue
What is the market cap of Organogenesis Holdings Inc?
The market capitalisation of Organogenesis Holdings Inc is USD 311,39M
What is the 1 year trading range for Organogenesis Holdings Inc share price?
Organogenesis Holdings Inc has traded in the range of US$ 2,04 to US$ 7,0771 during the past year
What is the PE ratio of Organogenesis Holdings Inc?
The price to earnings ratio of Organogenesis Holdings Inc is -22,16
What is the cash to sales ratio of Organogenesis Holdings Inc?
The cash to sales ratio of Organogenesis Holdings Inc is 0,65
What is the registered address of Organogenesis Holdings Inc?
The registered address for Organogenesis Holdings Inc is 85 Dan Road, Canton, Massachusetts, 02021
What is the Organogenesis Holdings Inc website address?
The website address for Organogenesis Holdings Inc is organogenesis.com
Which industry sector does Organogenesis Holdings Inc operate in?
Organogenesis Holdings Inc operates in the Pharmaceuticals sector

ORGO Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion